A compound of formula I in any of its stereoisomeric forms or one of its mixtures in any ratio, or one of its pharmaceutically acceptable salts, wherein in formula I: ring A, which comprises the two carbon atoms common to the ring A and the cycloalkenyl ring in formula I, is a 5 or 6 membered aromatic ring containing 1 or 2 nitrogen atoms as ring heteroatoms, or a 5 member aromatic ring containing 1 ring heteroatom which is a oxygen or sulfur atom, or 2 heteroatoms in the ring, one of which is a nitrogen atom and another of which is an oxygen or sulfur atom； R1 and R4 are independently selected from each other from the group consisting of: an atom of H； a C1-C10 alkyl group, a C2-C10 alkenyl group and an unsubstituted and at least monosubstituted C2-C10 alkynyl group, the substituents of which are selected from the group consisting of an atom of F, an OH group , a C1-C8 alkoxy group, a C1-C8-mercapto alkyl group, a -CN group, a COOR6 group, a CONR7R8 group, and unsubstituted and at least monosubstituted phenyl and heteroaryl groups in which the substituents of the phenyl and heteroaryl groups are selected from the group consisting of a halogen atom, a -CN group, a C1-C3 alkyl group, a C1-C3 alkoxy group and a CF3 group； unsubstituted and at least monosubstituted phenyl and heteroaryl groups, whose substituents are selected from the group consisting of a halogen atom, a -CN group, a C1-C3 alkyl group, a C1-C3 alkoxy group and a CF3 group； a COR9 group； a CONR10R11 group； a COOR12 group； a CF3 group； a halogen atom； a group - CN； an NR13R14 group； an OR15 group； an S (O) group mR16； a group SO2NR17R18； and a NO2 group； but they cannot be a halogen atom, a -CN group or a NO2 group if R1 or R4 are linked to a ring nitrogen atom； R2 and R3 are independently selected from each other from the group consisting of: an atom of H； a halogen atom； a group -CN； an unsubstituted and at least monosubstituted C1-C10 alkyl group, whose substituents are selected from the group consis
